

Launched in 2022, **myC** (*my Cancer my Concern*) is a Cancer Patients Europe (CPE) initiative that aims to raise awareness of the benefits and values of genomic testing in cancer, educate patients and stakeholders, and improve accessibility to genomic testing across Europe. The **Genomics and Breast Cancer European Patients Survey** is the first step of the myC initiative and part of CPE's broader goal to improve the management of cancer for patients across Europe.



KEY FINDING

4 out of 5 breast cancer patients eligible for genomic testing were not told it was available to them.



1,383 respondents completed the survey in 5 countries.

83%
with breast cancer

50%
eligible for genomic testing

65%
aged 40-59

A LACK OF AWARENESS OF GENOMIC TESTING

59%
had not heard about personalised or precision medicine.

55%
did not know the difference between genetic and genomic testing.

63%
had not heard about genomic testing in cancer.

Of breast cancer patients eligible for genomic testing...

84%
did not have enough information to make a decision.

75%
did not take a genomic test.

PATIENTS NEED MORE MEDICAL INFORMATION

49%
either did not find or only sometimes found the information they needed in a way that they could understand.

Medical professionals and the internet were top sources of medical information.

During their breast cancer journey, patients would have liked more information on:

